(LAZ) Lazard - Overview
Stock: Financial Advisory, Asset Management
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 4.20% |
| Yield on Cost 5y | 7.67% |
| Yield CAGR 5y | 1.56% |
| Payout Consistency | 96.2% |
| Payout Ratio | 62.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 34.9% |
| Relative Tail Risk | -5.59% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.35 |
| Alpha | -15.77 |
| Character TTM | |
|---|---|
| Beta | 1.694 |
| Beta Downside | 1.941 |
| Drawdowns 3y | |
|---|---|
| Max DD | 44.24% |
| CAGR/Max DD | 0.43 |
Description: LAZ Lazard January 08, 2026
Lazard Ltd. (NYSE: LAZ) is a global financial advisory and asset-management firm operating across the Americas, Europe, Middle East, Africa, and Asia-Pacific. It is organized into two core segments: Financial Advisory, which provides M&A, capital-markets, restructuring, sovereign and strategic advice to a broad client base across industries such as technology, healthcare, energy and real estate; and Asset Management, which delivers equity, fixed-income, multi-asset and alternative investment solutions to corporations, sovereign wealth funds, endowments, and high-net-worth individuals.
Key operating metrics from the most recent fiscal year (2023) show total revenue of roughly $1.5 billion, with advisory fees contributing about 60 % and investment-management fees the remaining 40 %. Assets under management (AUM) stood at approximately $260 billion, up 5 % YoY, reflecting strong inflows into ESG-focused and private-equity strategies. The business is sensitive to macro drivers: a robust M&A pipeline and stable interest-rate environments boost advisory demand, while heightened market volatility and regulatory scrutiny of alternative assets can pressure fee income.
For a deeper quantitative assessment of Lazard’s valuation dynamics, you may find ValueRay’s analytics platform useful.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 236.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -7.28 > 1.0 |
| NWC/Revenue: 49.12% < 20% (prev 55.73%; Δ -6.61% < -1%) |
| CFO/TA 0.10 > 3% & CFO 482.5m > Net Income 236.8m |
| Net Debt (1.15b) to EBITDA (440.8m): 2.62 < 3 |
| Current Ratio: 2.90 > 1.5 & < 3 |
| Outstanding Shares: last quarter (107.6m) vs 12m ago 1.41% < -2% |
| Gross Margin: 31.17% > 18% (prev 0.35%; Δ 3082 % > 0.5%) |
| Asset Turnover: 64.88% > 50% (prev 64.38%; Δ 0.50% > 0%) |
| Interest Coverage Ratio: 3.51 > 6 (EBITDA TTM 440.8m / Interest Expense TTM 87.6m) |
Altman Z'' 3.79
| A: 0.31 (Total Current Assets 2.37b - Total Current Liabilities 816.0m) / Total Assets 4.94b |
| B: 0.30 (Retained Earnings 1.49b / Total Assets 4.94b) |
| C: 0.06 (EBIT TTM 307.6m / Avg Total Assets 4.87b) |
| D: 0.31 (Book Value of Equity 1.22b / Total Liabilities 3.95b) |
| Altman-Z'' Score: 3.79 = AA |
Beneish M -2.67
| DSRI: 1.10 (Receivables 897.8m/800.3m, Revenue 3.16b/3.09b) |
| GMI: 1.13 (GM 31.17% / 35.09%) |
| AQI: 1.33 (AQ_t 0.44 / AQ_t-1 0.33) |
| SGI: 1.02 (Revenue 3.16b / 3.09b) |
| TATA: -0.05 (NI 236.8m - CFO 482.5m) / TA 4.94b) |
| Beneish M-Score: -2.67 (Cap -4..+1) = A |
What is the price of LAZ shares?
Over the past week, the price has changed by +5.02%, over one month by +8.80%, over three months by +14.01% and over the past year by +10.37%.
Is LAZ a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 3
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the LAZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 59.6 | 7.9% |
| Analysts Target Price | 59.6 | 7.9% |
| ValueRay Target Price | 63.1 | 14.1% |
LAZ Fundamental Data Overview February 01, 2026
P/E Forward = 14.3678
P/S = 1.6448
P/B = 5.78
P/EG = 1.0002
Revenue TTM = 3.16b USD
EBIT TTM = 307.6m USD
EBITDA TTM = 440.8m USD
Long Term Debt = 1.69b USD (from longTermDebt, two quarters ago)
Short Term Debt = 485.1m USD (from shortTermDebt, last quarter)
Debt = 2.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.15b USD (from netDebt column, last quarter)
Enterprise Value = 6.08b USD (5.10b + Debt 2.66b - CCE 1.67b)
Interest Coverage Ratio = 3.51 (Ebit TTM 307.6m / Interest Expense TTM 87.6m)
EV/FCF = 13.01x (Enterprise Value 6.08b / FCF TTM 467.6m)
FCF Yield = 7.69% (FCF TTM 467.6m / Enterprise Value 6.08b)
FCF Margin = 14.81% (FCF TTM 467.6m / Revenue TTM 3.16b)
Net Margin = 7.50% (Net Income TTM 236.8m / Revenue TTM 3.16b)
Gross Margin = 31.17% ((Revenue TTM 3.16b - Cost of Revenue TTM 2.17b) / Revenue TTM)
Gross Margin QoQ = 21.91% (prev 34.71%)
Tobins Q-Ratio = 1.23 (Enterprise Value 6.08b / Total Assets 4.94b)
Interest Expense / Debt = 0.85% (Interest Expense 22.7m / Debt 2.66b)
Taxrate = 36.18% (30.7m / 85.0m)
NOPAT = 196.3m (EBIT 307.6m * (1 - 36.18%))
Current Ratio = 2.90 (Total Current Assets 2.37b / Total Current Liabilities 816.0m)
Debt / Equity = 3.04 (Debt 2.66b / totalStockholderEquity, last quarter 873.7m)
Debt / EBITDA = 2.62 (Net Debt 1.15b / EBITDA 440.8m)
Debt / FCF = 2.47 (Net Debt 1.15b / FCF TTM 467.6m)
Total Stockholder Equity = 765.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.87% (Net Income 236.8m / Total Assets 4.94b)
RoE = 30.96% (Net Income TTM 236.8m / Total Stockholder Equity 765.0m)
RoCE = 12.54% (EBIT 307.6m / Capital Employed (Equity 765.0m + L.T.Debt 1.69b))
RoIC = 8.12% (NOPAT 196.3m / Invested Capital 2.42b)
WACC = 8.18% (E(5.10b)/V(7.76b) * Re(12.16%) + D(2.66b)/V(7.76b) * Rd(0.85%) * (1-Tc(0.36)))
Discount Rate = 12.16% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.44%
[DCF Debug] Terminal Value 75.19% ; FCFF base≈601.7m ; Y1≈524.2m ; Y5≈421.2m
Fair Price DCF = 66.22 (EV 7.37b - Net Debt 1.15b = Equity 6.22b / Shares 93.9m; r=8.18% [WACC]; 5y FCF grow -15.74% → 2.90% )
EPS Correlation: -7.81 | EPS CAGR: -6.99% | SUE: -1.40 | # QB: 0
Revenue Correlation: 50.38 | Revenue CAGR: 7.27% | SUE: 2.62 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.75 | Chg30d=-0.065 | Revisions Net=-5 | Analysts=8
EPS current Year (2026-12-31): EPS=3.67 | Chg30d=-0.182 | Revisions Net=-8 | Growth EPS=+50.2% | Growth Revenue=+17.2%
EPS next Year (2027-12-31): EPS=4.86 | Chg30d=-0.043 | Revisions Net=-7 | Growth EPS=+32.5% | Growth Revenue=+10.8%